Hologic/$HOLX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Hologic
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Ticker
$HOLX
Sector
Primary listing
Employees
7,063
Headquarters
Website
Hologic Metrics
BasicAdvanced
$16B
30.61
$2.41
0.63
-
Price and volume
Market cap
$16B
Beta
0.63
52-week high
$82.66
52-week low
$51.90
Average daily volume
3.4M
Financial strength
Current ratio
3.555
Quick ratio
2.59
Long term debt to equity
52.021
Total debt to equity
51.812
Interest coverage (TTM)
7.86%
Profitability
EBITDA (TTM)
1,241.7
Gross margin (TTM)
60.86%
Net profit margin (TTM)
13.79%
Operating margin (TTM)
23.43%
Effective tax rate (TTM)
17.54%
Revenue per employee (TTM)
$570,000
Management effectiveness
Return on assets (TTM)
6.69%
Return on equity (TTM)
11.38%
Valuation
Price to earnings (TTM)
30.614
Price to revenue (TTM)
4.182
Price to book
3.42
Price to tangible book (TTM)
29.52
Price to free cash flow (TTM)
18.426
Free cash flow yield (TTM)
5.43%
Free cash flow per share (TTM)
4.011
Growth
Revenue change (TTM)
1.29%
Earnings per share change (TTM)
-17.18%
3-year revenue growth (CAGR)
-8.23%
10-year revenue growth (CAGR)
4.34%
3-year earnings per share growth (CAGR)
-25.85%
10-year earnings per share growth (CAGR)
17.89%
What the Analysts think about Hologic
Analyst ratings (Buy, Hold, Sell) for Hologic stock.
Bulls say / Bears say
Blackstone and TPG agreed to acquire Hologic for $76 per share in cash—about a 6% premium over the previous closing price—with a potential additional $3 via contingent rights, indicating strong buyout valuation support (Reuters).
Reuters reported that Hologic’s molecular diagnostics division continues to deliver robust results despite challenges in the breast health business, demonstrating resilience in its core business segment (Reuters).
Hologic increased its adjusted EPS guidance for fiscal 2025 to $4.23–$4.26 and narrowed its full-year revenue outlook to $4.08 billion–$4.09 billion, reflecting strong demand for its diagnostic and surgical products (Reuters).
Hologic lowered its fiscal 2025 revenue forecast to $4.05 billion–$4.10 billion, citing weak demand for its breast health products, which caused its shares to fall 5% after hours (Reuters).
Persistent supply chain issues—including hurricane-related saline shortages and shipping delays for skeletal health products—could disrupt procedures in the breast, surgical, and skeletal health divisions (Reuters).
Shareholders face uncertainty around a potential extra $3 per share Contingent Value Right, which depends on Hologic meeting specific breast health revenue milestones in FY 2026 and FY 2027 (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2025.
Hologic Financial Performance
Revenues and expenses
Hologic Earnings Performance
Company profitability
Hologic News
AllArticlesVideos
Hologic Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Hologic, Inc. - HOLX
Business Wire2 weeks ago
HOLX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Hologic, Inc. Is Fair to Shareholders
Business Wire2 weeks ago
Blackstone, TPG to Buy Hologic for Up to $18.3 Billion
WSJ2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Hologic stock?
Hologic (HOLX) has a market cap of $16B as of November 03, 2025.
What is the P/E ratio for Hologic stock?
The price to earnings (P/E) ratio for Hologic (HOLX) stock is 30.61 as of November 03, 2025.
Does Hologic stock pay dividends?
No, Hologic (HOLX) stock does not pay dividends to its shareholders as of November 03, 2025.
When is the next Hologic dividend payment date?
Hologic (HOLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Hologic?
Hologic (HOLX) has a beta rating of 0.63. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.